NKG2D in NK and T cell-mediated immunity

Journal of Clinical Immunology

Volumn 25, Issue 6, 2005, Pages 534-540

  Ogasawara, Kouetsu ^a,b   Lanier, Lewis L ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

Author keywords

Autoimmunity; Bone marrow transplantation; DAP10; MICA; NK cells; NKG2D; RAE 1; T cell

Indexed keywords

CD8 ANTIGEN; LECTIN; MEMBRANE PROTEIN; NATURAL KILLER CELL RECEPTOR NKG2D;

ALLOGENIC BONE MARROW TRANSPLANTATION; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CELLULAR IMMUNITY; GRAFT REJECTION; HUMAN; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR IMMUNOLOGY; VIRUS IMMUNITY; VIRUS INFECTION;

ANIMALS; AUTOIMMUNE DISEASES; GRAFT REJECTION; HUMANS; IMMUNITY, CELLULAR; KILLER CELLS, NATURAL; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; T-LYMPHOCYTES;

EID: 29444455376     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-005-8786-4     Document Type: Review

References (76)

1. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T: Activation of natural killer cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727-730, 1999
2. Wu J, Song Y, Bakker AB, Bauer S, Spies T, Lanier LL, Phillips JH: An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285:730-732, 1999
3. Jamieson AM, Diefenbach A, McMahon CW, Xiong N, Carlyle JR, Raulet DH: The role of the NKG2D immunoreceptor in immune cell activation and natural killing. Immunity 17:19-29, 2002
4. Houchins JP, Yabe T, McSherry C, Bach FH: DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J Exp Med. 173:1017-1020, 1991
5. Diefenbach A, Tomasello E, Lucas M, Jamieson AM, Hsia JK, Vivier E, Raulet DH: Selective associations with signaling proteins determine stimulatory versus costimulatory activity of NKG2D. Nat Immunol 3:1142-1149, 2002
6. Gilfillan S, Ho EL, Cella M, Yokoyama WM, Colonna M: NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat Immunol 3:1150-1155, 2002
7. Rosen DB, Araki M, Hamerman JA, Chen T, Yamamura T, Lanier LL: A structural basis for the association of DAP12 with mouse, but not human, NKG2D. J Immunol 173:2470-2478, 2004
8. Wu J, Cherwinski H, Spies T, Phillips JH, Lanier LL: DAP10 and DAP12 form distinct, but functionally cooperative, receptor complexes in natural killer cells. J Exp Med 192:1059-1068, 2000
9. Garrity D, Call ME, Feng J, Wucherpfennig KW: The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc Natl Acad Sci USA 102:7641-7646, 2005
10. Wu J, Song Y, Bakker ABH, Bauer S, Groh V, Spies T, Lanier LL, Phillips JH: An activating receptor complex on natural killer and T cells formed by NKG2D and DAP10. Science 285:730-732, 1999
11. Chang C, Dietrich J, Harpur AG, Lindquist JA, Haude A, Loke YW, King A, Colonna M, Trowsdale J, Wilson MJ: Cutting edge: KAP10, a novel transmembrane adapter protein genetically linked to DAP12 but with unique signaling properties. J Immunol 163:4651-4654, 1999
12. Lanier LL, Corliss BC, Wu J, Leong C, Phillips JH: Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells. Nature 391:703-707, 1998
13. Cerwenka A, Lanier LL: NKG2D ligands: Unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 61:335-343, 2003
14. Raulet DH: Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol 3:781-790, 2003
15. Lanier LL: NK Cell recognition. Annu Rev Immunol 23:225-274, 2005
16. Malarkannan S, Shih PP, Eden PA, Horng T, Zuberi AR, Christianson G, Roopenian D, Shastri N: The molecular and functional characterization of a dominant minor H antigen, H60. J Immunol 161:3501-3509, 1998
17. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL, Spies T: Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 285:727-729, 1999
18. Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ: ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 14:123-133, 2001
19. Radosavljevic M, Cuillerier B, Wilson MJ, Clement O, Wicker S, Gilfillan S, Beck S, Trowsdale J, Bahram S: A cluster of ten novel MHC class I related genes on human chromosome 6q24.2-q25.3. Genomics 79:114-123, 2002
20. Jan Chalupny N, Sutherland CL, Lawrence WA, Rein-Weston A, Cosman D: ULBP4 is a novel ligand for human NKG2D. Biochem Biophys Res Commun 305:129-135, 2003
21. Bacon L, Eagle RA, Meyer M, Easom N, Young NT, Trowsdale J: Two human ULBP/RAET1 molecules with transmembrane regions are ligands for NKG2D. J Immunol 173:1078-1084, 2004
22. Cerwenka A, Bakker AB, McClanahan T, Wagner J, Wu J, Phillips JH, Lanier LL: Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12:721-727, 2000
23. Diefenbach A, Jamieson AM, Liu SD, Shastri N, Raulet DH: Ligands for the murine NKG2D receptor: Expression by tumor cells and activation of NK cells and macrophages. Nat Immunol 1:119-126, 2000
24. Carayannopoulos LN, Naidenko OV, Fremont DH, Yokoyama WM: Cutting edge: Murine UL16-binding protein-like transcript. 1: A newly described transcript encoding a high-affinity ligand for murine NKG2D. J Immunol 169:4079-4083, 2002
25. Hamerman JA, Ogasawara K, Lanier LL: Cutting edge: Toll-like receptor signaling in macrophages induces ligands for the NKG2D receptor. J Immunol 172:2001-2005, 2004
26. Lodoen M, Ogasawara K, Hamerman JA, Arase H, Houchins JP, Mocarski ES, Lanier LL: NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J Exp Med 197:1245-1253, 2003
27. Lodoen MB, Abenes G, Umamoto S, Houchins JP, Liu F, Lanier LL: The cytomegalovirus m155 gene product subverts natural killer cell antiviral protection by disruption of H60-NKG2D interactions. J Exp Med 200:1075-1081, 2004
28. Krmpotic A, Busch DH, Bubic I, Gebhardt F, Hengel H, Hasan M, Scalzo AA, Koszinowski UH, Jonjic S: MCMV glycoprotein gp40 confers virus resistance to CD8+ T cells and NK cells in vivo. Nat Immunol 3:529-535, 2002
29. Dandekar AA, O'Malley K, Perlman S: Important roles for gamma interferon and NKG2D in gammadelta T-cell-induced demyelination in T-cell receptor beta-deficient mice infected with a coronavirus. J Virol 79:9388-9396, 2005
30. Groh V, Bahram S, Bauer S, Herman A, Beauchamp M, Spies T: Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc Natl Acad Sci USA 93:12445-12450, 1996
31. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T: Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB. Proc Natl Acad Sci U S A 96:6879-6884, 1999
32. Groh V, Rhinehart R, Randolph-Habecker J, Topp MS, Riddell SR, Spies T: Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells. Nat Immunol 2:255-260, 2001
33. Das H, Groh V, Kuijl C, Sugita M, Morita CT, Spies T, Bukowski JF: MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function. Immunity 15:83-93, 2001
34. Gasser S, Orsulic S, Brown EJ, Raulet DH: The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature, 436:1186-1190, 2005
35. Groh V, Bruhl A, El-Gabalawy H, Nelson JL, Spies T: Stimulation of T cell autoreactivity by anomalous expression of NKG2D and its MIC ligands in rheumatoid arthritis. Proc Natl Acad Sci USA 100:9452-9457, 2003
36. Ogasawara K, Hamerman JA, Ehrlich LR, Bour-Jordan H, Santamaria P, Bluestone JA, Lanier LL: NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 20:757-767, 2004
37. Krmpotic A, Hasan M, Loewendorf A, Saulig T, Halenius A, Lenac T, Polic B, Bubic I, Kriegeskorte A, Pernjak-Pugel E, Messerle M, Hengel H, Busch DH, Koszinowski UH, Jonjic S: NK cell activation through the NKG2D ligand MULT-1 is selectively prevented by the glycoprotein encoded by mouse cytomegalovirus gene m145. J Exp Med 201:211-220, 2005
38. Rolle A, Mousavi-Jazi M, Eriksson M, Odeberg J, Soderberg-Naucler C, Cosman D, Karre K, Cerboni C: Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: Up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein. J Immunol 171:902-908, 2003
39. Dunn C, Chalupny NJ, Sutherland CL, Dosch S, Sivakumar PV, Johnson DC, Cosman D: Human cytomegalovirus glycoprotein UL16 causes intracellular sequestration of NKG2D ligands, protecting against natural killer cell cytotoxicity. J Exp Med 197:1427-1439, 2003
40. Wu J, Chalupny NJ, Manley TJ, Riddell SR, Cosman D, Spies T: Intracellular retention of the MHC class I-related chain B ligand of NKG2D by the human cytomegalovirus UL16 glycoprotein. J Immunol 170:4196-4200, 2003
41. Welte SA, Sinzger C, Lutz SZ, Singh-Jasuja H, Sampaio KL, Eknigk U, Rammensee HG, Steinle A: Selective intracellular retention of virally induced NKG2D ligands by the human cytomegaloviras UL16 glycoprotein. Eur J Immunol 33:194-203, 2003
42. Zou Y, Bresnahan W, Taylor RT, Stastny P: Effect of human cytomegalovirus on expression of MHC class I-related chains A. J Immunol 174:3098-3104, 2005
43. Siren J, Sareneva T, Pirhonen J, Strengell M, Veckman V, Julkunen I, Matikainen S: Cytokine and contact-dependent activation of natural killer cells by influenza A or Sendai virus-infected macrophages. J Gen Virol 85:2357-2364, 2004
44. Cerwenka A, Baron JL, Lanier LL: Ectopic expression of retinoic acid early inducible-1 gene (RAE-1) permits natural killer cell-mediated rejection of a MHC class I-bearing tumor in vivo. Proc Natl Acad Sci USA 98:11521-11526, 2001
45. Diefenbach A, Jensen ER, Jamieson AM, Raulet DH: Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413:165-171, 2001
46. Smyth MJ, Swann J, Kelly JM, Cretney E, Yokoyama WM, Diefenbach A, Sayers TJ, Hayakawa Y: NKG2D recognition and perforin effector function mediate effective cytokine immunother-apy of cancer. J Exp Med 200:1325-1335, 2004
47. Takaki R, Hayakawa Y, Nelson A, Sivakumar PV, Hughes S, Smyth MJ, Lanier LL: JL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J Immunol 175:2167-2173, 2005
48. Pende D, Rivera P, Marcenaro S, Chang CC, Biassoni R, Conte R, Kubin M, Cosman D, Ferrone S, Moretta L, Moretta A: Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: Analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 62:6178-6186, 2002
49. Westwood JA, Kelly JM, Tanner JE, Kershaw MH, Smyth MJ, Hayakawa Y: Cutting edge: Novel priming of tumor-specific immunity by NKG2D-triggered NK cell-mediated tumor rejection and Th1-independent CD4+ T cell pathway. J Immunol 172:757-761, 2004
50. Smyth MJ, Swann J, Cretney E, Zerafa N, Yokoyama WM, Hayakawa Y: NKG2D function protects the host from tumor initiation. J Exp Med, 202:583-588, 2005
51. Groh V, Wu J, Yee C, Spies T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419:734-738, 2002
52. Salih HR, Rammensee HG, Steinle A: Cutting edge: Down-regulation of MICA on human tumors by proteolytic shedding. J Immunol 169:4098-4102, 2002
53. Doubrovina ES, Doubrovin MM, Vider E, Sisson RB, O'Reilly RJ, Dupont B, Vyas YM: Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma. J Immunol 171:6891-6899, 2003
54. Ogasawara K, Hamerman JA, Hsin H, Chikuma S, Hour-Jordan H, Chen T, Pertel T, Carnaud C, Bluestone JA, Lanier LL: Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity 18:41-51, 2003
55. Ogasawara K, Benjamin J, Takaki R, Phillips JH, Lanier LL: Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts. Nat Immunol, 6:938-945, 2005
56. Oppenheim DE, Roberts SJ, Clarke SL, Filler R, Lewis JM, Tigelaar RE, Girardi M, Hayday AC: Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat Immunol 6:928-937, 2005
57. Wiemann K, Mittrucker HW, Feger U, Welte SA, Yokoyama WM, Spies T, Rammensee HG, Steinle A: Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J Immunol 175:720-729, 2005
58. Castriconi R, Cantoni C, Della Chiesa M, Vitale M, Marcenaro E, Conte R, Biassoni R, Bottino C, Moretta L, Moretta A: Transforming growth factor beta 1 inhibits expression of NKp30 and NKG2D receptors: Consequences for the NK-mediated killing of dendritic cells. Proc Natl Acad Sci USA 100:4120-4125, 2003
59. Lee JC, Lee KM, Kim DW, Heo DS: Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients. J Immunol 172:7335-7340, 2004
60. Kiessling R, Hochman PS, Haller O, Shearer GM, Wigzell H, Cudkowicz G: Evidence for a similar or common mechanism for natural killer cell activity and resistance to hemopoietic grafts. Eur J Immunol 7:655-663, 1977
61. Lotzova E, Savary CA, Pollack SB: Prevention of rejection of allogeneic bone marrow transplants by NK 1.1 antiserum. Transplantation 35:490-494, 1983
62. Murphy WJ, Kumar V, Bennett M: Acute rejection of murine bone marrow allografts by natural killer cells and T cells. Differences in kinetics and target antigens recognized. J Exp Med 166:1499-1509, 1987
63. Cudkowicz G, Stimpfling JH: Induction of immunity and of unresponsiveness to parental marrow grafts in adult F-1 hybrid mice. Nature 204:450-453, 1964
64. Cudkowicz G, Bennett M: Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice. J Exp Med 134:1513-1528, 1971
65. Rembecki RM, Kumar V, David CS, Bennett M: Bone marrow cell transplants involving intra-H-2 recombinant inbred mouse strains. Evidence that hemopoietic histocompatibility-1 (Hh-1) genes are distinct from H-2D or H-2L. J Immunol 141:2253-2260, 1988
66. Sentman CL, Kumar V, Bennett M: Rejection of bone marrow cell allografts by natural killer cell subsets: 5E6+ cell specificity for Hh-1 determinant 2 shared by H-2d and H-2f. Eur J Immunol 21:2821-2828, 1991
67. Yu YYL, Kumar V, Bennett M: Murine natural killer cells and marrow graft rejection. Annu Rev Immunol 10:189-214, 1992
68. Raziuddin A, Longo DL, Mason L, Ortaldo JR, Murphy WJ: Ly-49 G2+ NK cells are responsible for mediating the rejection of H-2b bone marrow allografts in mice. Int Immunol 8:1833-1839, 1996
69. Nowbakht P, Ionescu MC, Rohner A, Kalberer CP, Rossy E, Mori L, Cosman D, De Libero G, Wodnar-Filipowicz A: Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 105:3615-3622, 2005
70. Poirot L, Benoist C, Mathis D: Natural killer cells distinguish innocuous and destructive forms of pancreatic islet autoimmunity. Proc Natl Acad Sci USA 101:8102-8107, 2004
71. Meresse B, Chen Z, Ciszewski C, Tretiakova M, Bhagat G, Krausz TN, Raulet DH, Lanier LL, Groh V, Spies T, Ebert EC, Green PH, Jabri B: Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 21:357-366, 2004
72. Setiady YY, Pramoonjago P, Tung KS: Requirements of NK cells and proinflammatory cytokines in T cell-dependent neonatal autoimmune ovarian disease triggered by immune complex. J Immunol 173:1051-1058, 2004
73. Shi FD, Wang HB, Li H, Hong S, Taniguchi M, Link H, Van Kaer L, Ljunggren HG: Natural killer cells determine the outcome of B cell-mediated autoimmunity. Nat Immunol 1:245-251, 2000
74. Hue S, Mention JJ, Monteiro RC, Zhang S, Cellier C, Schmitz J, Verkarre V, Fodil N, Bahram S, Cerf-Bensussan N, Caillat-Zucman S: A direct role for NKG2D/MICA interaction in villous atrophy during celiac disease. Immunity 21:367-377, 2004
75. Roberts AI, Lee L, Schwarz E, Groh V, Spies T, Ebert EC, Jabri B: Cutting edge: NKG2D receptors induced by IL-15 costimulate CD28- negative effector CTL in the tissue microenvironment. J Immunol 167:5527-5530., 2001
76. Anderson MS, Bluestone JA: The NOD mouse: A model of immune dysregulation. Annu Rev Immunol 23:447-485, 2005